EAI-045 is the fourth-generation EGFR inhibitor overcoming T790M and C797S resistance [1]. EAI045 is an allosteric inhibitor that targets selected drug-resistant EGFR mutants but spares the wild-type receptor [2]. When combined with cetuximab that blocks EGFR dimerization, EAI-045 markedly reduces tumor growth in a mouse model of EGFR L858R/T790M and L858R/T790M/C797S-mutant-driven lung cancer [1].

EAI-045 is the fourth-generation EGFR inhibitor overcoming T790M and C797S resistance [1]. EAI045 is an allosteric inhibitor that targets selected drug-resistant EGFR mutants but spares the wild-type receptor [2]. When combined with cetuximab that blocks EGFR dimerization, EAI-045 markedly reduces tumor growth in a mouse model of EGFR L858R/T790M and L858R/T790M/C797S-mutant-driven lung cancer [1].